Abstract:Introduction. As growing numbers of patients are at higher risk of infection, novel topical broad-spectrum antimicrobials are urgently required for wound infection management. Robust pre-clinical studies should support the development of such novel antimicrobials. Gap statement. To date, evidence of robust investigation of the cytotoxicity and antimicrobial spectrum of activity of antimicrobial peptides (AMP)s is lacking in published literature. Using a more clinical lens, we address this gap in experimental approach, building on our experience with poly- l -lysine (PLL)-based AMP polymers. Aim. To evaluate the in vitro bactericidal activity and cytotoxicity of a PLL-based 16-armed star AMP polymer, designated 16-PLL 10 , as a novel candidate antimicrobial. Methods. Antimicrobial susceptibilities of clinical isolates and reference strains of ESKAPE ( Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , Enterobacter spp.) pathogens, to 16-PLL 10 were investigated. Human erythrocyte haemolysis and keratinocyte viability assays were used to assess toxicity. Modifications were made to 16-PLL 10 and re-evaluated for improvement. Results. Minimum bactericidal concentration of 16-PLL 10 ranged from 1.25 μM to ≥25 μM. At 2.5 μM, 16-PLL 10 was broadly bactericidal against ESKAPE strains/wound isolates. Log-reduction in colony forming units (c.f.u.) per millilitre after 1 h, ranged from 0.3 ( E. cloacae ) to 5.6 ( K. pneumoniae ). At bactericidal concentrations, 16-PLL 10 was toxic to human keratinocyte and erythrocytes. Conjugates of 16-PLL 10 , Trifluoroacetylated (TFA)−16-PLL 10 , and Poly-ethylene glycol (PEG)ylated 16-PLL 10 , synthesised to address toxicity, only moderately reduced cytotoxicity and haemolysis. Conclusions. Due to poor selectivity indices, further development of 16-PLL 10 is unlikely warranted. However, considering the unmet need for novel topical antimicrobials, the ease of AMP polymer synthesises/modification is attractive. To support more rational development, prioritising clinically relevant pathogens and human cells, to establish selective toxicity profiles in vitro , is critical. Further characterisation and discovery utilising artificial intelligence and computational screening approaches can accelerate future AMP nanomaterial development.

Development of a defibrinated human blood hemolysis assay for rapid testing of hemolytic activity compared to computational prediction

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides

Rapid Assessment of Susceptibility of Bacteria and Erythrocytes to Antimicrobial Peptides by Single-Cell Impedance Cytometry

Cytotoxicity Assays as Predictors of the Safety and Efficacy of Antimicrobial Agents

Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity

Prediction of Hemolysis Tendency of Peptides using a Reliable Evaluation Method

Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides

Engineering Antimicrobial Peptides with Improved Antimicrobial and Hemolytic Activities

Lactic Dehydrogenase in the in Vitro Evaluation of Hemolytic Properties of Ventricular Assist Device

Machine learning-guided discovery and design of non-hemolytic peptides

Development of High Content Imaging Methods for Cell Death Detection in Human Pluripotent Stem Cell-Derived Cardiomyocytes

Development and application of a high-content biology-based assay to quantify effects of modulators of NETosis in primary human neutrophils

Label-free Assessment of Complement-Dependent Cytotoxicity of Therapeutic Antibodies via a Whole-Cell MALDI Mass Spectrometry Bioassay

A comprehensive battery of flow cytometric immunoassays for the in vitro testing of chemical effects in human blood cells

Prediction of Hemolytic Peptides and their Hemolytic Concentration (HC50)

Blood Compatibility—An Important but Often Forgotten Aspect of the Characterization of Antimicrobial Peptides for Clinical Application

Improved Method for the ASTM Platelet and Leukocyte Assay: Use of Minimal Heparinization in a Screening Test for Hemocompatibility of Blood-Contacting Medical Devices

Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device

A New Robust Method for Predicting Hemolytic Toxicity from Peptide Se-quence

Antimicrobial spectrum against wound pathogens and cytotoxicity of star-arranged poly-l-lysine-based antimicrobial peptide polymers